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Background and objectives: Sexually transmitted infections (STIs) contribute largely to the burden of health in
South Africa and are recognized as major contributors to the human immunodeficiency virus (HIV) epidemic. Young
women are particularly vulnerable to STIs. The purpose of this secondary analysis was to examine the risk factors
associated with prevalent and incident STIs among women who had participated in three clinical trials.
Methods: A total of 5,748 women were screened and 2293 sexually active, HIV negative, non-pregnant women
were enrolled in three clinical trials in Kwazulu-Natal, South Africa. The prevalence of individual STIs Chlamydia
trachomatis (CT), Neisseria gonorrhea (NG), syphilis, and Trichomonas vaginalis (TV) was assessed at screening; and
incident infections were evaluated over a 24 month period.
Results: Overall, the combined study population of all three trials had a median age of 28 years (inter-quartile
range (IQR):22–37), and a median duration of follow-up of 12 months. Prevalence of STIs (CT, NG, TV, or syphilis)
was 13% at screening. The STI incidence was estimated to be 20/100 women years. Younger women (<25 years,
p < 0.001), women who were unmarried (p < 0.001) and non-cohabiting women (p < 0.001) were shown to be at
highest risk for incident STIs.
Conclusions: These results confirm the extremely high prevalence and incidence of STIs among women living in
rural and urban communities of KwaZulu-Natal, South Africa, where the HIV epidemic is also particularly severe.
These findings strongly suggest an urgent need to allocate resources for STI and HIV prevention that mainly target
younger women.
Trial registration: Clinical Trials.gov, NCT00121459.
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South Africa (SA) is at the epicenter of the human im-
munodeficiency virus (HIV) epidemic; and other sexually
transmitted infections (STIs) continue to be endemic
[1-3]. STIs have been associated with pelvic inflamma-
tory disease, adverse pregnancy outcomes, cervical can-
cer, infertility, and multiple reproductive tract sequelae
[4]. Furthermore, the evidence that STIs facilitate HIV
acquisition and transmission [5,6] enhances the serious-
ness of the problem.* Correspondence: sarita.naidoo@mrc.ac.za
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unless otherwise stated.KwaZulu-Natal (KZN), the most densely populated
province in SA, has been markedly affected by both the
HIV and STI epidemic [7,1]; with a disproportionate
burden of STIs and HIV among women. Several studies
conducted within various populations of women in KZN
have shown high prevalence of HIV coupled with STIs
[8-11]. Control of STIs therefore remains extremely im-
portant in these high risk populations. Availability of
data on the epidemiology of STIs and associated risk fac-
tors in these populations is thus essential for the devel-
opment of successful targeted interventions in this
region.
This study presents combined data from a large cohort
of women, from urban and rural areas of KZN, whoLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lence and incidence of STIs [(Chlamydia trachomatis
(CT), Neisseria gonorrhea (NG), syphilis, and Trichomo-
nas vaginalis (TV)] and the associated risk factors. This
data provides an opportunity to gain further insights into
the overall STI prevalence and incidence in this region;
and will inform the design of future HIV/STI prevention




This analysis includes women who participated in three
multi-centre trials at sites in KZN: Methods for Improv-
ing Reproductive Health in Africa (MIRA) trial [12],
conducted in rural Umkomaas and Botha’s Hill; Microbi-
cides Development Programme (MDP) Feasibility study
in preparation for Phase III Microbicide Trials [13], in
semi-rural Tongaat and Verulam; and HIV Prevention
Trials Network (HPTN) Site Preparedness study (HPTN
055) for future implementation of Phase 2/IIb/III HIV
Prevention Studies [14], in an urban area in Durban and
in a rural district of Hlabisa. Study populations were de-
scribed elsewhere in detail [12-14].
Study procedures
Study procedures were described in detail elsewhere
[12-14]. Main inclusion criteria were similar in all three
studies, and briefly included being sexually active; HIV
negative at screening; not pregnant, willing to provide
written consent, and follow study procedures. Informa-
tion on demographics and sexual behaviors were col-
lected. Participants received risk reduction counseling
and condoms; and treatment was provided for curable,
symptomatic or laboratory-diagnosed STIs. Women di-
agnosed as HIV-positive were referred to local health
care facilities for further care and support. Male partners
were encouraged to access the trial sites for counseling,
HIV testing and STI treatment. Additionally, women di-
agnosed with STIs were given referrals for their partners
to access treatment at local clinics. Study protocols and
informed consent forms were approved by the local eth-
ics committee and various Institutional Review Boards.
Laboratory procedures
STI and HIV testing was described previously for each
study [12,15,16]. Briefly, in the MIRA trial, [16] CT, GC
and TV were detected by PCR (Roche Pharmaceuticals,
Branchburg, NJ, USA) and syphilis by rapid plasma re-
agin (RPR) and Treponema pallidum haemagglutinin
(TPHA) (Randox Laboratories, Crumlin, UK). In HPTN
055 [15], CT and GC were detected using the BDProbe
Tec ET assay (Becton Dickinson, MD), TV by wet mount
microscopy and syphilis by RPR and confirmatory TPHA.In MDP Feasibility [16], CT and GC were detected using
PCR (COBAS Amplicor, Roche Molecular Diagnostics,
Pleasanton, CA, USA), TV by wet mount microscopy and
syphilis by RPR and confirmatory TPHA (Omega Diag-
nostics, Alva, UK).Statistical analysis
Differences in proportions were tested using the chi-
square test. The Student’s t test was used to compare av-
erages. Univariate and multivariate logistic regression
analyses were conducted to identify variables predictive
of any STI (CT, NG, TV or Syphilis) infection at screen-
ing. Only variables determined to be consistent across
the studies were included.
STI incidence was determined as the first positive test
after a negative test at enrollment. Associations between
various factors and STI incidence were described using
Kaplan-Meier survival plots and log-rank tests. Risk factors
for STI incidence were assessed using Cox proportional
hazard regression models. Multivariate models considered
all variables statistically significant (p < 0.05) in initial ana-
lyses and used forward stepwise methods. Statistical
analysis was performed using STATA Release 8.2 (Stata
Statistical Software: Stata Corporation, College Station,
Texas, USA).Results
Of the 5,748 women screened, 3492 were from the MIRA
trial, 1221 from MDP Feasibility; and 1035 from HPTN055.
Overall, the women had a median age of 28 years (inter-
quartile range (IQR):22–37), and a median duration of
follow-up of 12 months (data not shown). Majority were
from rural areas (91%); unmarried (85%); and not living
with regular sexual partners (non-cohabiting) (68%). Over
half (53%) reported less than high school education. HIV
and STI (diagnosed with at least one STI: CT, NG, TV or
syphilis) prevalence at baseline was 42% (2407/5748) and
13% (738/5748), respectively.Risk factors for STIs at screening
Women with prevalent STIs (≥1) were younger (<25 years)
(p < 0.001); reported less than high school education
(p < 0.0001), were unmarried (p < 0.0001); and non-
cohabiting (p < 0.0001) (Table 1). Table 2 shows that
women who were HIV positive, <25 years of age; un-
married; non- cohabiting; and who reported less than
high school education were significantly associated
with increased risk of having a prevalent STI (Odds
Ratios (OR):1.50, 95% Confidence Intervals (CI):1.27-
1.76; OR:1.36, 95% CI:1.11-1.68; OR:1.60, 95% CI:1.14-
2.24; OR:1.27,95% CI:1.03-1.60; and OR:1.75, 95%
CI:1.49-2.06 respectively).




N = 5,748 (%) N = 728 (%) N = 5,020 (%)
HIV prevalence at screening 2,407 (42) 375 (52) 2,032 (40) <0.001
District 0.524
Rural‡ 5216 (91) 656 (90) 4560 (91)
Urbanᆕ 532 (9) 72 (10) 460 (9)
Age, mean (SD) 28.6 (8) 26 (7) 29 (8)
Age groups (years)
≤ 24 2,223 (39) 367 (50) 1856 (37) <0.001
25-34 2,224 (39) 255 (35) 1969 (39)
35+ 1,305 (22) 106 (15) 1199 (24)
Education
Less than high school 3069 (53) 467 (61) 2602 (52) <0.0001
Marital status
Not married 4,912 (85) 677 (93) 4235 (84) <0.0001
Co-habitation status
Non-cohabiting 3,929 (68) 566 (78) 3363 (70) <0.0001
†Diagnosis of chlamydia, gonorrhea, trichomonas or syphilis.
‡Hlabisa, Umkomaas, Botha’s Hill, Tongaat and Verulam.
ᆕDurban.
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Crude STI incidence amongst the 2293 enrolled women
was 680 (20/100 women-years). Kaplan-Meier survival
curves of infection stratified by age, marital, and co-
habitation status are shown in Figure 1a-c. The highest
incidence rate was observed for women <25 years old
(26/100 women-years, p < 0.001), followed by moderately








HIV positive 1.56 (1.34-1.83) <
Age (years)
<25 1.60 (1.33-1.92) 0
25 - 34 1.17 (0.95-1.43) 0
35+ 1 -
Education
Less than high school 1.67 (1.42-1.96) <
Marital status
Not married 2.47 (1.84-3.32) <
Co-habitation status
Non-cohabiting 1.73 (1.43-2.07) <
CI, confidence interval; OR, odds ratio.women (22/100 women-years, p < 0.001 and 21/100
women-years, p < 0.001; respectively).
Table 3 shows that baseline STI infection, being <25 years
of age; unmarried; and non-use of contraception were sig-
nificantly associated with increased risk of acquiring inci-
dent STIs (OR:1.52, 95% CI:1.22-1.88; OR:1.40, 95%
CI:1.14-1.74; OR:1.54, 95% CI:1.22-1.94 and OR:1.40, 95%






0.0001 1.50 (1.27-1.76) <0.0001
.000 1.36 (1.11-1.68) 0.003
.137 1.08 (0.87-1.34) 0.480
1 -
0.00001 1.75 (1.49-2.06) <0.0001
0.0001 1.60 (1.14-2.24) 0.006








































Figure 1 The Kaplan-Meier survival curves of STI incidence stratified by age (a), marital status (b) and cohabitation status (c).
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HR (95% CI) HR (95% CI)
Any STI at baseline 1.61 (1.30-2.00) - 1.52 (1.22-1.88) 0.000
Age
≤25 1.64 (1.36-2.00) <0.001 1.40 (1.14-1.74) 0.001
25-34 1.19 (0.97-1.46) 0.100 1.10 (0.89-1.37) 0.370
35+ 1 -
District
Rural 0.93 (0.69-1.25) 0.628 -
Urban 1 -
Employed/income
No 1.35 (1.10-1.66) 0.0038 -
Yes 1 -
Level of education
High school or more 1 -
Less than high school 1.25 (1.06-1.46) 0.006 -
Contraceptive use
At least one form of contraceptive1 1 -
None 1.33 (1.13-1.55) <0.001 1.40 (1.19-1.64) 0.000
Marital status
Married 1 -
Not married 1.84 (1.49-2.27) <0.0001 1.54 (1.22-1.94) 0.000
Cohabitation status
Yes 1 -
No 1.43 (1.21-1.68) <0.0001 -
Condom used during last sexual act
No 1.00 (0.86-1.16) 0.98 -
Yes 1 -
CI, confidence interval; HR Hazard ratio.
1including condom, injectables, pills, traditional methods.
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ment status, condom use and education level.
Discussion
Our analysis confirms that STI prevalence and incidence
is extremely high in women living in KZN. The preva-
lence of STIs was 13% while the incidence rate was 20/
100 women-years. Similar STI incidence was reported in
other studies conducted in SA [15,17-19]. Incidence of
STIs in this cohort was unacceptably high despite
provision of risk reduction counseling, condoms, treat-
ment for curable STIs; and partner treatment or referral.
In this study, women who were <25 years; unmarried;
and non-cohabiting were identified as being at most risk for
STI acquisition. Recent evidence from a PrEP trial, VOICE,
conducted in SA, Zimbabwe and Uganda, showed the same
risk factors associated with increased risk of HIV acquisition
[20]. Similarly, Feldblum and colleagues [19] observed thatyounger age was associated with incident HIV and STIs.
Another study also showed that younger women were at
higher risk of acquiring new STIs [18]. Studies in Tanzania
[21], Kenya [22] and Brazil [23] reported that being unmar-
ried was associated with STI acquisition.
Predictably, having an STI at baseline also placed
women at increased risk of acquiring an STI during fol-
low up, and at substantial risk of HIV acquisition. HIV
infection at screening was associated with a significantly
higher prevalence among women diagnosed with at least
one STI compared to those who had no STI; providing
further evidence for the relationship between HIV and
STIs. Mlisana and colleagues [17] reported a similar
finding. It was also previously suggested that HIV pre-
vention efforts in SA may be enhanced by screening STI
patients for acute HIV infection [6].
This study defined populations who are most at risk of
STI acquisition and broadly showed the common risk
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suggesting the need for effective behavioural or biomed-
ical interventions. This data will aide in the design of fu-
ture interventions in these populations; and contributes
to the STI surveillance data for women in this region.
Our study has several limitations. These results may
not be representative of the wider population as these
women were recruited from selected populations. How-
ever this large data set, together with the numerous STIs
detected, provides valuable information on the STI epi-
demic in this region. Another limitation is the slight var-
iations in testing methods used for STI diagnosis in the
different trials, where some methods may have been
more sensitive than others. Additionally, the risk factor
analyses were restricted to socio-demographic and be-
havioral variables that were assessed consistently across
all three studies, possibly resulting in reducing the power
of the analyses to detect significant associations. Finally,
although all STIs were treated, there was no information
on partner infection status or resistant infections during
follow up.
Conclusions
Due to the high incidence of STIs observed in this popula-
tion, targeted interventions aimed at young women and
their partners, are urgently needed. Control and treatment
of STIs still remains an important public health priority
for HIV prevention and should include a combination of
prevention efforts such as extensive health education, con-
dom promotion, male circumcision, and HIV and STI
testing in all patient-provider encounters.
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